1. Imugene (IMU) - PH's first child. B-Cell technology platform has been de-risked. Very undervalued at current MC. Drug supply deals with Merck KGaA, Pfizer and Merck & Co. Collaborations with Eureka Therapeutics and Celularity. The closest of the three to signing a deal with big pharma. World class management and SAB.
2. Chimeric Therapeutics (CHM) - Early stage. High risk. Has the potential to be bigger and better than IMU. World class management and SAB.
3. Radiopharm Theranostics (RAD) - Not invested and not interested. PH has enough of my $$$ invested in his companies...hahaha
Paul Hopper IP opportunists CHM VS RAD, page-2
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.39M | |||
| Open | High | Low | Value | Volume |
| 1.8¢ | 1.9¢ | 1.7¢ | $66.72K | 3.721M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 500356 | 1.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.9¢ | 471412 | 5 |
View Market Depth
| Last trade - 16.10pm 04/06/2024 (20 minute delay) ? |
|
|||||
|
Last
1.8¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 1.7¢ | 1.8¢ | 1.7¢ | 579076 | ||
| Last updated 15.44pm 04/06/2024 ? | |||||
| CHM (ASX) Chart |